• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

高危肝细胞癌辅助治疗方案的比较：贝叶斯网状meta 分析和系统评价。

Comparison of adjuvant treatment regimens for high-risk hepatocellular carcinoma: a Bayesian network meta analysis and systematic review.

机构信息

Department of Interventional Therapy, The First Hospital of Jilin University, Changchun, Jilin, China.

Department of Radiology, The First Hospital of Jilin University, Changchun, Jilin, China.

出版信息

Front Immunol. 2024 Nov 11;15:1487353. doi: 10.3389/fimmu.2024.1487353. eCollection 2024.

DOI:10.3389/fimmu.2024.1487353
PMID:39588371
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11586331/
Abstract

BACKGROUND

The five-year recurrence rate for patients with hepatocellular carcinoma (HCC) is as high as 70%. Patients with high-risk recurrence factors experience significantly poorer prognosis. Local regional therapies, including transarterial chemoembolisation (TACE), hepatic arterial infusion chemotherapy (HAIC), radiotherapy, and emerging immunotherapy, are commonly used adjuvant treatment options. We conducted an indirect comparison of these adjuvant therapies for such patients.

METHODS

We conducted a systematic search in public databases for relevant studies and assessed the efficacy and safety of the corresponding therapies by consolidating disease-free survival (DFS), overall survival (OS), and adverse events (AEs).

RESULTS

A total of eight randomised controlled trials were ultimately included. The Gelman-Rubin plot and kernel density estimation indicate that the stability of the combined model is satisfactory.

CONCLUSION

immunotherapy is not inferior to local regional therapies in delaying tumour recurrence, however, the higher incidence of AEs remains a significant concern. Adjuvant radiotherapy demonstrated superior efficacy in delaying tumour recurrence compared to adjuvant TACE, although further support from phase III clinical trial evidence is required.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/prospero/, identifier CRD42024576316.

摘要

背景

肝细胞癌（HCC）患者的五年复发率高达 70%。具有高危复发因素的患者预后明显较差。局部区域治疗，包括经动脉化疗栓塞（TACE）、肝动脉灌注化疗（HAIC）、放疗和新兴的免疫治疗，是常用的辅助治疗选择。我们对这些辅助治疗方法进行了间接比较。

方法

我们在公共数据库中进行了系统搜索，以评估相应治疗方法的疗效和安全性，方法是整合无病生存率（DFS）、总生存率（OS）和不良事件（AEs）。

结果

最终纳入了八项随机对照试验。Gelman-Rubin 图和核密度估计表明组合模型的稳定性令人满意。

结论

免疫疗法在延缓肿瘤复发方面并不逊于局部区域治疗，但更高的不良事件发生率仍然是一个重大关注点。与辅助 TACE 相比，辅助放疗在延缓肿瘤复发方面显示出更好的疗效，但需要来自 III 期临床试验证据的进一步支持。

系统评价注册

https://www.crd.york.ac.uk/prospero/，标识符 CRD42024576316。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/e69dafdddceb/fimmu-15-1487353-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/74a9b69837aa/fimmu-15-1487353-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/0a5850899f66/fimmu-15-1487353-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/1802ef6c9f77/fimmu-15-1487353-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/9c36e59d17df/fimmu-15-1487353-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/22752ae54906/fimmu-15-1487353-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/70e621e93789/fimmu-15-1487353-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/406a4aa37b01/fimmu-15-1487353-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/e69dafdddceb/fimmu-15-1487353-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/74a9b69837aa/fimmu-15-1487353-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/0a5850899f66/fimmu-15-1487353-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/1802ef6c9f77/fimmu-15-1487353-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/9c36e59d17df/fimmu-15-1487353-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/22752ae54906/fimmu-15-1487353-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/70e621e93789/fimmu-15-1487353-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/406a4aa37b01/fimmu-15-1487353-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3dd1/11586331/e69dafdddceb/fimmu-15-1487353-g008.jpg

相似文献

1
Comparison of adjuvant treatment regimens for high-risk hepatocellular carcinoma: a Bayesian network meta analysis and systematic review.高危肝细胞癌辅助治疗方案的比较：贝叶斯网状meta 分析和系统评价。
Front Immunol. 2024 Nov 11;15:1487353. doi: 10.3389/fimmu.2024.1487353. eCollection 2024.
2
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.早期和极早期肝细胞癌的消融和非手术治疗：系统评价和网络荟萃分析。
Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.
3
Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.系统治疗不可切除肝细胞癌的序贯治疗：随机临床试验的系统评价和贝叶斯网络荟萃分析。
Crit Rev Oncol Hematol. 2024 Dec;204:104522. doi: 10.1016/j.critrevonc.2024.104522. Epub 2024 Sep 26.
4
External beam radiotherapy for unresectable hepatocellular carcinoma.不可切除肝细胞癌的外照射放疗
Cochrane Database Syst Rev. 2017 Mar 7;3(3):CD011314. doi: 10.1002/14651858.CD011314.pub2.
5
Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.不同经动脉栓塞疗法单独或联合局部消融或辅助全身治疗对不可切除肝细胞癌的比较疗效：一项随机对照试验的网状Meta分析
PLoS One. 2017 Sep 21;12(9):e0184597. doi: 10.1371/journal.pone.0184597. eCollection 2017.
6
Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.早期或极早期肝细胞癌患者的管理：一项网络荟萃分析尝试
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011650. doi: 10.1002/14651858.CD011650.pub2.
7
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.中期肝细胞癌患者的管理：一项网络荟萃分析尝试
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD011649. doi: 10.1002/14651858.CD011649.pub2.
8
The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma.经导管动脉化疗栓塞术（TACE）联合热消融与单纯 TACE 治疗肝细胞癌的疗效比较。
Cochrane Database Syst Rev. 2022 Jan 4;1(1):CD013345. doi: 10.1002/14651858.CD013345.pub2.
9
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
10
A systematic overview of chemotherapy effects in colorectal cancer.结直肠癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367.

引用本文的文献

1
Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma.辅助性肝动脉灌注化疗与经动脉化疗栓塞术预防肝细胞癌手术切除后早期复发的比较
J Hepatocell Carcinoma. 2025 Jul 16;12:1425-1439. doi: 10.2147/JHC.S510814. eCollection 2025.

本文引用的文献

1
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.辅助信迪利单抗治疗切除术后高危肝细胞癌的随机、对照、Ⅱ期临床试验
Nat Med. 2024 Mar;30(3):708-715. doi: 10.1038/s41591-023-02786-7. Epub 2024 Jan 19.
2
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).原发性肝癌诊疗指南（2022年版）
Liver Cancer. 2023 Apr 5;12(5):405-444. doi: 10.1159/000530495. eCollection 2023 Oct.
3
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
阿替利珠单抗联合贝伐珠单抗对比主动监测用于治疗接受手术切除或消融治疗的高风险肝细胞癌患者（IMbrave050）：一项随机、开放标签、多中心、III 期临床试验。
Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20.
4
Preoperative prediction and risk assessment of microvascular invasion in hepatocellular carcinoma.肝细胞癌微血管侵犯的术前预测和风险评估。
Crit Rev Oncol Hematol. 2023 Oct;190:104107. doi: 10.1016/j.critrevonc.2023.104107. Epub 2023 Aug 24.
5
Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.系统治疗晚期肝细胞癌指南推荐的批判性评价：综述。
JAMA Oncol. 2024 Mar 1;10(3):395-404. doi: 10.1001/jamaoncol.2023.2677.
6
Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study.辅助免疫检查点抑制剂与术后肝细胞癌（PREVENT）无复发生存率的提高相关：一项前瞻性、多中心队列研究。
J Gastroenterol. 2023 Oct;58(10):1043-1054. doi: 10.1007/s00535-023-02018-2. Epub 2023 Jul 14.
7
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌预防、诊断和治疗实践指南。
Hepatology. 2023 Dec 1;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466. Epub 2023 May 22.
8
Predictors of early and late hepatocellular carcinoma recurrence.预测早期和晚期肝细胞癌复发的因素。
World J Gastroenterol. 2023 Feb 28;29(8):1243-1260. doi: 10.3748/wjg.v29.i8.1243.
9
Salvage locoregional therapies for recurrent hepatocellular carcinoma.挽救性局部区域治疗复发性肝细胞癌。
World J Gastroenterol. 2023 Jan 21;29(3):413-424. doi: 10.3748/wjg.v29.i3.413.
10
Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy.肝切除术后复发风险高的肝细胞癌辅助抗程序性死亡蛋白1（PD-1）抗体治疗
Hepatol Int. 2023 Apr;17(2):406-416. doi: 10.1007/s12072-022-10478-6. Epub 2023 Jan 16.